Connect with us

Technology

Frost & Sullivan Released Report: “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”

Published

on

SHANGHAI, Sept. 2, 2024 /PRNewswire/ — Frost & Sullivan released a report, titled “BiBo Pharma: A Global CDMO Leading in Advanced Biopharmaceutical Manufacturing Technologies”. The report explores a global CDMO leading the “The Fourth Revolutionary Wave of Biologics Manufacturing” and pioneering the next generation of CDMO models.

The global biomanufacturing capacity gap and budget constraints have ignited the “The Fourth Revolutionary Wave of Biologics Manufacturing”, with production sites expanding towards million-liter scales. In this context, Contract Development and Manufacturing Organizations (CDMOs) have become key players in global biomanufacturing. In 2023, BiBo Pharma, founded in Boston, USA, introduced a new generation of ultra-large production platforms, marking a new era in biomanufacturing. BiBo Pharma is breaking capacity barriers and reducing antibody drug production costs from the international average of hundreds of dollars to just $10 per gram, offering disruptive solutions to global biopharmaceutical companies.

Part I: BiBo Pharma 1.0 : Reflecting on the Past – Originating in Boston, USA, and Navigating through the Global CDMO development Journey

In the increasingly competitive CDMO industry, BiBo Pharma continues to advance. This success is due not only to their precise grasp of market opportunities but also to their breakthroughs in core biopharmaceutical industrialization technologies. Sailing from Boston, BiBo Pharma has been committed to the commercial production of biologics since its inception. The company independently designed and manufactured the ultra-large stainless steel bioreactors and pioneers a new generation of production models. In 2023, BiBo Pharma successfully completed the construction of a 30,000L single-tank ultra-large-production line, and in March 2024, it successfully commenced operations.

BiBo Pharma developed a comprehensive technology platform for microbial fermentation, mammalian cell culture, gene therapy, and antibody-drug conjugates (ADC). This platform offers one-stop services from DNA to IND/BLA and large-scale commercial production. To date, BiBo Pharma has offered CDMO services for more than 130 large molecule projects. Their operations adhere to international quality and management standards, solidifying BiBo Pharma’s position on the global CDMO stage after a decade of dedicated effort, and pioneering the next generation of CDMO models.

Part II: BiBo Pharma 2.0: Current Focus – Upgrading Strategies and Expanding Capabilities

//30,000L Capacity Advantage and Global First Delivery Advantage as an Industry Pioneer//

Major global CDMOs are expanding their large-scale commercial production capacities by focusing on the construction of large-scale stainless steel bioreactors. The future direction involves advancing from the current 15,000L reactors to fourth-generation ultra-large-scale production technologies.

BiBo Pharma is the first and only CDMO to deliver a new generation of ultra-large stainless steel bioreactors with a maximum working volume of 30,000L per tank. This is an engineering scale-up of over 2.5 times compared to the current 15,000L (total volume) standard in large-scale biopharmaceutical production. BiBo Pharma leverages economies of scale and cost-sharing to offer a potential solution to reduce costs on the basis of ensuring independently designed core equipment and a controllable supply chain.

PanFlex®-Engineering: Breaking Through the “Quality-Cost-Efficiency” Triangle  

The conventional factory construction process adopts an engineering design model that proceeds from the top level down to the lower levels. PanFlex®-Engineering employs a “Process is King” strategy, using standardized units to reverse-engineer a complete factory. As a result, PanFlex®-Engineering system transcends the impossible triangle of “quality-cost-efficiency.” Remarkably, it took less than 18 months to deliver a 30,000L ultra-large production platform, roughly half the time and cost of similar projects worldwide. In addition, the 30,000L platform passed quality audits from the U.S., EU, and Chinese clients. Leveraging its PanFlex®-Operation system, Bibo Pharma achieved a “Right on First Time” in March 2024 when the platform was put into operation with a 100% success rate in subsequent production.

Grand-CHO Platform: A “Three-in-one” Approach to Innovation

A “Three-in-One” approach to innovation——Grand-CHO Platform involves advances in cell line development, process research, and production technology for ultra-large-scale platforms.

Grand-CHO platform improves cell line expression and stability, optimizes commercial production processes of different scales, and offers other benefits. The second-generation Epic-CHO cell line achieves a high expression level of 10 g/L at the mini-pool stage and offers more than double the stability of leading international cell lines, laying a solid foundation for large-scale production.

Grand-CHO technology enables high-density and large-scale cell storage, while seamlessly integrating a 3,000L N-1 perfusion process and a 30,000L intensified Fed-batch production process. Compared to traditional methods, Grand-CHO technology reduces production cycle time by 30%, doubles the yield per fermentation volume, and cuts restart time for 30,000L projects from 60 days to 30 days. Grand-CHO technology, integrated with the 30,000L ultra-large-scale production line, is fundamentally transforming the overall production efficiency of biopharmaceuticals.  

Pulse Continuous Manufacturing (PCM)

The combination of BiBo Pharma’s PanFlex®-Engineering and Grand-CHO technology has led to a groundbreaking production model — Pulse Continuous Manufacturing (PCM). PCM releases a single high-volume batch upstream, such as 60,000 liters per pulse (60kL/P). It then processes multiple downstream batches continuously based on each unit’s operation time. PCM significantly improves production efficiency, boosting overall line efficiency by 50% to 300%. PCM’s success is driven by the interconnected equipment enabled by PanFlex®-Engineering. Additionally, BiBo’s P03 plant has implemented an automated process control system (PAS) that enables full digital integration across the facility, making the execution of the PCM model more efficient and seamless. 

Technology Integration Drives Reduction of Antibody Drug Production Cost to $10 per Gram

The primary initiative to solve the constraints of production costs, is the international breakthrough of the first-ever 30,000L single-tank ultra-large-scale production line. Integrating PanFlex®-Engineering, Grand-CHO technology, and a pulse continuous production mode, BiBo Pharma reduce antibody drug production cost from hundreds of dollars to $10 per gram.

An Engineering and Technical Service Provider

BiBo Pharma has launched the pioneering “Blue Whale Program,” a financial risk-free manufacturing solution powered by the PanFlex® system. This program offers tailored production line construction services to global clients, which reduces the construction costs and timelines by 50%. This allows clients to postpone capital expenditure decisions from Phase I/II to Phase III of clinical trials, giving them more time to make informed investment choices. Additionally, the program provides a risk reduction feature: fees paid by clients are refundable regardless of whether the product succeeds in the market. This effectively offers additional insurance for commercialization and mitigates risks in the R&D and production phases.

Part III: BiBo Pharma 3.0: Shaping the Future – Establishing Comprehensive Technology Industry Advantages and Leading the Next Chapter

BiBo Pharma establishes an intensive production model, which underpins the company a diversified, full-technology platform offering one-stop CDMO services. With its Boston R&D center and global production capabilities, BiBo Pharma delivers high-quality services adhering to international standards. BiBo Pharma utilizes its unparalleled industry advantages to empower the global biopharmaceutical companies by reshaping the cost structure of biologics.

Additionally, the “Blue Whale Program” expands BiBo Pharma’s established engineering solutions, reaching more clients with commercial production needs. Frost & Sullivan expects that these capabilities and advantages will position BiBo Pharma as the best solution for global pharmaceutical companies in the future.

To read the full content, go here: https://www.frost.com/news/press-releases/bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies/

Media Contact
Contact: Qian Li
Company Name: Frost & Sullivan
Website: http://www.frostchina.com
Email: qian.li@frostchina.com 

View original content:https://www.prnewswire.com/apac/news-releases/frost–sullivan-released-report-bibo-pharma-a-global-cdmo-leading-in-advanced-biopharmaceutical-manufacturing-technologies-302235863.html

SOURCE Frost & Sullivan

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Pillsbury Notice of Data Breach

Published

on

By

NEW YORK, July 18, 2026 /PRNewswire/ — Pillsbury Winthrop Shaw Pittman LLP (“Pillsbury”) was among many law firms targeted by sophisticated social engineering attempts in an incident last year. While the firm quickly detected and blocked the activity, an unauthorized actor was able to access some of the firm’s documents during a short window of time. Pillsbury notified any impacted clients last year and undertook a detailed process to review the accessed documents for personal information. Pillsbury then began notifying individuals whose personal information was affected. That process is now complete, and today, Pillsbury is publishing substitute notice as a final step.

For more information, please visit the substitute notice on our website at https://www.pillsburylaw.com/en/breach-notice.html

View original content to download multimedia:https://www.prnewswire.com/news-releases/pillsbury-notice-of-data-breach-302828892.html

SOURCE Pillsbury Winthrop Shaw Pittman LLP

Continue Reading

Technology

From Remote Racing to Embodied AI: Fibocom and Intedigo Bring 5G Bidirectional Data Transmission into Real-World Applications

Published

on

By

SHANGHAI, July 18, 2026 /PRNewswire/ — From July 17 to 20, Fibocom and Intedigo will jointly present a cross-regional, beyond-visual-line-of-sight (BVLOS) teleoperation demonstration at Booth H3-C408 during the World Artificial Intelligence Conference (WAIC) 2026. Visitors will be able to enter a remote driving cockpit and control a real race car located at HURA PARK in Jiading, Shanghai, steering, accelerating, and braking in real time while experiencing how 5G connectivity enables remote operation.

More than an immersive driving experience, the demonstration provides a live validation of 5G bidirectional data transmission for embodied AI teleoperation. The vehicle continuously sends live track video, vehicle status, and operating data to the remote cockpit, while control commands are transmitted back to the vehicle, creating a closed-loop teleoperation system. Stable, low-latency, and highly reliable connectivity is essential for high-dynamic maneuvers such as high-speed cornering, precision braking, and continuous lane changes.

Developed by Intedigo, the remote driving system connects a real race car with an immersive remote driving cockpit. It supports 1080p@60Hz video transmission, glass-to-glass (G2G) video latency of less than 80 ms, and control latency of less than 10 ms. The demanding racing environment magnifies differences in video continuity and control responsiveness, making communications performance directly perceptible, measurable, and verifiable.

At the joint demonstration, Fibocom’s FM160 5G module provides cellular connectivity for the system. Powered by the Qualcomm Snapdragon™ X62 5G Modem-RF System, the FM160 supports SA and NSA network architectures as well as 3GPP Release 16. On the downlink, it supports NR Carrier Aggregation (NR CA) with bandwidth of up to 120 MHz, delivering peak speeds of up to 3.5 Gbps in NSA mode and 2.5 Gbps in SA mode. On the uplink, it supports UL MIMO and delivers peak speeds of up to 900 Mbps in SA mode. These capabilities support the continuous transmission of HD video and vehicle status data, along with reliable delivery of control commands.

As embodied AI moves into factories, data centers, logistics operations, and industrial parks, robots are becoming increasingly capable of performing tasks autonomously. Yet complex environments, unexpected events, and edge cases still require Human-in-the-Loop (HITL) remote intervention to help ensure safe and reliable operation.

Daniel Liu, CEO of Intedigo, said:

“5G represents the pinnacle of human communications and the starting point of machine communications. In the past, communications connected people to people; in the future, they will connect people to robots and robots to robots. Remote racing is simply the easiest entry point for people to understand this concept. What we are truly validating is a communications system capable of supporting remote collaboration for embodied AI. HURA makes low-latency remote driving a tangible experience, while RoBOX extends this capability to robots and a broader range of intelligent terminals. Together with Fibocom, we hope to enable more machines to receive remote assistance whenever needed while remaining continuously connected and operating reliably.”

Simon Tao, VP of Wireless Solutions Business Group and General Manager of MBB BU at Fibocom, said:

“As embodied AI enters real-world industrial environments, reliable connectivity will become the foundation for telemetry feedback, remote control and operational management. Fibocom’s 5G solutions, represented by FM160, provide the cellular connectivity required for continuous on-site data transmission and reliable control command delivery. Fibocom will continue collaborating with ecosystem partners such as Intedigo to bring cellular connectivity to more robots, autonomous machines and mobile intelligent terminals, enabling embodied AI systems to stay continuously connected and respond reliably in real-world applications.”

From remote race cars to robots, unmanned equipment, and mobile intelligent terminals, 5G is evolving from connecting people to connecting machines. This joint demonstration makes the capabilities of 5G bidirectional data transmission directly perceptible, experiential, and verifiable, helping pave the way for embodied AI to scale across real-world applications.
 

About Fibocom

Fibocom, founded in 1999, is China’s first wireless communication module company listed on both the A-share and H-share markets (300638.SZ, 0638.HK). As a global leading provider of wireless communication modules and AI solutions, Fibocom leverages wireless communication and artificial intelligence as its core technologies to provide integrated hardware and software solutions that empower industry applications. These solutions accelerate the transformation from “Connect Everything” to “Intelligent Connectivity” across diverse industries.

Fibocom’s one-stop solutions encompass cellular communication, AI, automotive, and GNSS modules, as well as AI toolchains, supporting industry-side and mainstream large model integration, and providing AI Agent, global connectivity, and cloud services, driving the digital intelligence upgrades in industries such as robotics, consumer electronics, low-altitude economy, intelligent transportation, smart retail, and smart energy.

View original content to download multimedia:https://www.prnewswire.com/news-releases/from-remote-racing-to-embodied-ai-fibocom-and-intedigo-bring-5g-bidirectional-data-transmission-into-real-world-applications-302828996.html

SOURCE Fibocom Wireless Inc.

Continue Reading

Technology

DR. PHONE FIX ANNOUNCES SECOND TRANCHE CLOSING OF NON-BROKERED CONVERTIBLE DEBENTURE UNIT FINANCING

Published

on

By

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

EDMONTON, AB, July 18, 2026 /CNW/ — Dr. Phone Fix Canada Corporation (“Dr. Phone Fix” or the “Company”) (TSXV: DPF) is pleased to announce that, further to its news release dated May 19, 2026 and June 24, 2026 (the “Prior News Releases”), it has closed the second tranche of its non-brokered private placement (the “Offering”) of convertible debenture units of the Company (each, a “Unit”). The Company issued 726 Units, at a price of $1,000 per Unit, for aggregate gross proceeds of $726,000. Each Unit is comprised of (i) one $1,000 principal amount unsecured convertible debenture of the Company (a “Convertible Debenture”) and (ii) 3,125 common share (“Common Share”) purchase warrants of the Company (each, a “Warrant”). Additional detail on the Offering, including terms of the Convertible Debentures and Warrants, is set out in the Prior News Releases.

In connection with the Offering, the Company paid a finder’s fee consisting of an aggregate cash fee of $50,820 and issued an aggregate of 317,625 common share purchase warrants of the Company (each, a “Finder’s Warrant”) to certain qualified arm’s length parties. Each Finder’s Warrant is exercisable to acquire one Common Share of the Company at an exercise price of $0.22 prior to the date that is 24 months from the date of issuance.

All securities issued pursuant to the Offering, including any Common Shares issuable upon conversion of the Convertible Debentures or exercise of the Warrants and Finder’s Warrants, are subject to a statutory hold period of four months and one day from the closing of the Offering, in accordance with applicable securities laws and TSX Venture Exchange (the “TSXV”) policies. 

The Offering remains subject to final acceptance of the TSXV.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Dr. Phone Fix

Dr. Phone Fix is a national, award-winning, eco-friendly, and customer-centric leader in Canada’s cell phone and electronics repair and certified pre-owned device industry. Founded in 2019, the Company now operates 44 retail locations nationwide through a standardized and scalable operating platform designed to support consistent execution across multiple markets, delivering fast, reliable, and environmentally conscious repair services alongside a curated selection of certified pre-owned devices and premium accessories. Dr. Phone Fix maintains strong partnerships with OEMs and certified suppliers, ensuring consistently high-quality standards across its national footprint. With a focus on responsible device lifecycle management, customer service, and operational discipline, Dr. Phone Fix continues to set the benchmark for device care and resale in Canada.

www.docphonefix.com

NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

Forward-Looking Information and Cautionary Statements

Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements relating to: the final acceptance of the Offering by the TSXV; and the expected use of proceeds following the closing of the Offering. Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the Company’s financial condition and development plans do not change as a result of unforeseen events; the TSXV will provide its final acceptance of the Offering; and the Company will be able to obtain the financing required in order to develop and continue its business and operations. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to obtain TSXV final acceptance for the Offering; the potential failure to complete the balance of the Offering or to raise the full anticipated gross proceeds; market conditions and investor demand for the Company’s securities; the Company’s inability to deploy the proceeds as currently intended; and general economic and market conditions. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

 

SOURCE Dr. Phone Fix

Continue Reading

Trending